Schiano Vittorio, Laurenzano Eugenio, Brevetti Gregorio, De Maio Julieta Isabel, Lanero Simona, Scopacasa Francesco, Chiariello Massimo
Department of Clinical Medicine and Cardiovascular and Immunological Sciences, University of Naples Federico II, Naples, Italy.
Clin Nutr. 2008 Apr;27(2):241-7. doi: 10.1016/j.clnu.2007.11.007. Epub 2008 Jan 31.
BACKGROUND & AIMS: Peripheral arterial disease (PAD) is strongly associated with endothelial dysfunction and inflammation, which portend a high cardiovascular risk. Accordingly, we investigated the effects of omega-3 polyunsaturated fatty acid (n-3 PUFA) supplementation on endothelial function and inflammatory status in affected individuals.
PAD patients were randomly divided into two groups. In Group I (n=16) pre-enrollment therapy was not modified, while in Group II (n=16) n-3 PUFAs 1 g b.i.d. for 3 months were added to the previous treatment. Endothelial function was assessed by measuring plasma soluble thrombomodulin (sTM) and brachial artery flow-mediated dilation (FMD), and the inflammatory status by measuring high-sensitivity C-reactive protein and myeloperoxidase.
In Group II, n-3 PUFAs reduced sTM levels from the median value of 33.0 ng/mL (interquartile range 16.7, 37.2) to 17.0 ng/mL (11.2, 33.7) (p=0.04), and improved FMD from 6.7% (3.7, 8.7) to 10.0% (6.2, 14.2) (p=0.02). Conversely, these markers did not change in Group I. After 3 months, the levels of inflammatory markers remained unmodified in both groups.
In PAD, n-3 PUFAs induced a marked improvement in endothelial function. Conversely, they did not affect the inflammatory status. In future, large, prospective studies are needed to investigate whether n-3 PUFAs, by improving endothelial function, would reduce the incidence of ischemic events in a population at high risk.
外周动脉疾病(PAD)与内皮功能障碍和炎症密切相关,预示着心血管风险较高。因此,我们研究了补充ω-3多不饱和脂肪酸(n-3 PUFA)对患病个体内皮功能和炎症状态的影响。
将PAD患者随机分为两组。第一组(n = 16)入组前治疗方案不变,而第二组(n = 16)在先前治疗基础上加用n-3 PUFAs,每日2次,每次1 g,共3个月。通过测量血浆可溶性血栓调节蛋白(sTM)和肱动脉血流介导的扩张(FMD)评估内皮功能,通过测量高敏C反应蛋白和髓过氧化物酶评估炎症状态。
在第二组中,n-3 PUFAs使sTM水平从中位数33.0 ng/mL(四分位间距16.7,37.2)降至17.0 ng/mL(11.2,33.7)(p = 0.04),并使FMD从6.7%(3.7,8.7)提高至10.0%(6.2,14.2)(p = 0.02)。相反,第一组中这些指标未发生变化。3个月后,两组炎症标志物水平均未改变。
在PAD患者中,n-3 PUFAs可显著改善内皮功能。相反,它们不影响炎症状态。未来需要进行大型前瞻性研究,以调查n-3 PUFAs是否通过改善内皮功能降低高危人群缺血事件的发生率。